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Abstract
Background
In the absence of a gold standard for the diagnosis of latent tuberculosis (TB) infection
(LTBI), the current tests available for the diagnosis of LTBI are limited by their inability to dif-
ferentiate between LTBI and active TB disease. We investigated IP-10 as a potential bio-
marker for LTBI among household contacts exposed to sputum positive active TB cases.
Methods
Active TB cases and contacts were recruited into a cohort with six months’ follow-up. Con-
tacts were tested for LTBI using QuantiFERON1-TB Gold In-Tube (QFN) assay and the
tuberculin skin test (TST). Baseline supernatants from the QFN assay of 237 contacts and
102 active TB cases were analysed forMycobacterium tuberculosis (MTB) specific and
mitogen specific IP-10 responses.
Results
Contacts with LTBI (QFN+TST+) had the highest MTB specific IP-10 responses at baseline,
compared to uninfected contacts (QFN-TST-) p<0.0001; and active cases, p = 0.01. Using a
cut-off of 8,239 pg/ml, MTB specific IP-10 was able to diagnose LTBI with a sensitivity of
87.1% (95% CI, 76.2–94.3) and specificity of 90.9% (95% CI, 81.3–96.6). MTB specific to
mitogen specific IP-10 ratio was higher in HIV negative active TB cases, compared to HIV
negative latently infected contacts, p = 0.0004. Concentrations of MTB specific IP-10 were
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Conclusion
IP-10 performed well in differentiating contacts with either latent or active TB from those
who were uninfected but was not able to differentiate LTBI from active disease except when
MTB specific to mitogen specific ratios were used in HIV negative adults. In addition, IP-10
had the potential to diagnose ‘recent TB infection’ in persons classified as having LTBI
using the TST. Such individuals with strong IP-10 responses would likely benefit from
chemoprophylaxis.
Introduction
It has been estimated that approximately one third of the world’s population is latently infected
withMycobacterium tuberculosis (MTB) [1]. Optimal diagnosis of latent tuberculosis infection
(LTBI) should be aimed at persons with the highest risk of progression to active tuberculosis
(TB) disease [2, 3] who will benefit from prompt treatment, and contribute to reduction in
transmission of the infection to others [4]. There is no gold standard test for the diagnosis of
LTBI [5, 6] and many are still using the tuberculin skin test (TST), despite its limitation of false
positive results secondary to prior exposure to environmental mycobacteria or Bacillus Calm-
ette–Guérin (BCG) immunisation [7]. The TST is also influenced by inter or intra reader vari-
ability and immunosuppression status of the host [8]. The other tests used to diagnose LTBI
are the interferon gamma release assays (IGRA). These have higher specificity than the TST [9]
because they use antigens from the RD1 region of the mycobacterial genome [10] such as early
secreted antigenic target 6 (ESAT-6) [11, 12] and culture filtrate protein 10 (CFP-10) [13], pro-
teins which are lacking in BCG [14, 15] and in many pathogenic environmental mycobacteria
includingMycobacterium avium [16].
There is good correlation between TST and IGRA in low TB endemic settings [17, 18] but
high levels of discordance have been reported in some high TB endemic areas including
Uganda [19]. Most of the discordance occurs with individuals having TST negative but IGRA
positive results [5], although some studies have reported the reverse [20–22]. The latter discor-
dance has been linked predominantly to BCG [9, 20, 23, 24] which has effects on TST but not
on IGRA [18, 20, 25–27]. Other studies report no effect of BCG on TST responses [28, 29].
Both tests are also influenced by the immunosuppression status of the host in particular by
immature immune systems, HIV infection, malnutrition, or diabetes mellitus [4].
The TST and IGRA rely on a good delayed-type hypersensitivity (DTH) or T cell immune
response following re-exposure to MTB specific antigens, respectively, and are unable to differ-
entiate between latent infection and active disease [5]. This has led to the search for new bio-
markers to improve the diagnosis of LTBI. One potential candidate is the interferon inducible
protein (IP) 10 (IP-10) [30, 31]. This is the chemokine (CXC motif) ligand 10 expressed by
macrophages when stimulated by interferons and other pro-inflammatory cytokines [32–34].
IP-10 induces movement of monocytes and activated Th1 cells to sites of inflammation
through its interaction with the CXC chemokine receptor 3 [35, 36]. IP-10 promotes Th1
immune responses by up regulating the expression of IFN-γ and is involved in the DTH
immune responses [37, 38]. It has been suggested that production of this chemokine in
response to MTB antigens could be used as a marker of infection [39, 40]. Although the use of
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IP-10 for the diagnosis of LTBI still depends on stimulation with MTB antigens, it is often
produced in high quantities, hence providing an amplified signal in immunosuppressed indi-
viduals and children [41]. However, some studies have showed low sensitivities of IP-10 in
detecting MTB infection among children with active TB disease in a low TB endemic setting
[42] and a high TB burden area [43, 44]. IP-10 has also been assessed as a potential biomarker
to monitor treatment response to TB medication, whereby IP-10 levels drop between the start
of treatment and end of treatment [39].
Our study population had highly discordant TST and IGRA (QuantiFERON1-TB Gold In-
Tube (QFN)) results which prompted us to explore the use of IP-10 as a potential biomarker
for the diagnosis of LTBI. We also assessed the performance of IP-10 in differentiating between
latently infected individuals and active TB cases or uninfected individuals.
Materials and Methods
Study design and participants
New sputum smear positive TB patients (active TB cases) aged above 18 years and attending
the TB clinics at two health centres in Kampala municipality, Uganda, and their healthy house-
hold contacts, were enrolled consecutively into a longitudinal cohort. The details of the study
settings have previously been described [45]. Both index cases and contacts provided a sample
of 3ml of blood for the QuantiFERON1-TB Gold In-Tube (QFN), test (Cellestis GmbH
(Europe), Hannover, Germany) at baseline and at the end of six months. A TST was placed on
the inner surface of the left forearms of the contacts based on the Mantoux method using 2
Tuberculin Units (0.1ml) of RT-23 PPD (Statens Serum Institute, Copenhagen, Denmark)
and read after 48–72 hours. The TST was repeated after six months. A positive response was
defined as a diameter of the induration area of>5 mm for HIV positive contacts and>10 mm
for those who were HIV negative.
Ethics statement
All index cases and household contacts that were above 18 years of age gave written informed
consent to participate in the study. For the household contacts that were below 18 years, the
parents and next of kin gave written informed consent on their behalf to participate in the
study. Children between 10 and 17 years gave additional written informed assent to participate
in the study. The study was approved by both the Makerere University Ethical Review Board
and Uganda National Council of Science and Technology.
IP-10 ELISA assay
Whole blood QFN culture supernatants from contacts and active TB cases at baseline and after
six months were analysed for IP-10 responses using Human IP-10 BD OptEIA™ ELISA kits
(BD Biosciences, USA) [46]. Samples were obtained from all the three QFN tubes (nil (no anti-
gen), antigen and mitogen) and analysed in duplicate wells using 96 well Immulon1 4 HBX
microtiter plates (Thermo Scientific™, USA). Fifty microliters (1:250) of diluted capture anti-
body (anti-human IP-10 monoclonal antibody) was added to each well and incubated over-
night at 4°C. After washing 3 times, 200 μl of assay diluent (10% fetal bovine serum (FBS) in
phosphate buffered saline (PBS)) was added to block the plates and then incubated for 1 hour
at room temperature. During this period, standard concentrations of IP-10 were prepared and
test samples were diluted in assay diluent (1:8). The plates were then washed 3 times and 50 μl
of standard or diluted sample was added to the wells and incubated for 2 hours. After 5 washes,
50 μl of working detector (biotinylated anti-human IP-10 monoclonal antibody + streptavidin-
IP-10 as a Biomarker in the Diagnosis of Latent Tuberculosis Infection
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horseradish peroxidase conjugate) diluted 1:250 in assay diluent was added and incubated for 1
hour. The plates were washed 7 times with 30 second to 1-minute soaks and 50 μl of substrate
solution added and incubated for 30 minutes at room temperature in the dark. After this, 50 μl
of stop solution (2N H2SO4) was added to each well and the plate optical densities (ODs) were
read at 450 nm and 570 nm within 30 minutes using an ELISA plate reader (Biotek). A stan-
dard curve was generated from the standards using Gen5™ Data Analysis Software and used to
convert ODs to IP-10 levels in pg/ml. The range of the standards (sensitivity of the assay) was
from 5.8954 pg/ml to 3,000 pg/ml.
The IP-10 values for each individual from the duplicate wells were averaged. The spontane-
ous (no antigen) IP-10 levels were subtracted from the stimulated (MTB specific antigen) and
the mitogen specific data to obtain net MTB specific, and mitogen specific IP-10 responses
respectively. The net MTB specific and mitogen specific IP-10 responses were both multiplied
by the dilution factor of 8 to obtain the final value.
Statistical methods
The study was designed to assess the use of IP-10 as a potential biomarker for the diagnosis of
LTBI. We divided the study subjects into: uninfected contacts (QFN-TST-), latently infected
contacts (QFN+TST+), contacts with discordant results (QFN+TST- or QFN-TST+), and the
active TB cases. The contacts that had discordant QFN and TST results were excluded from
further analysis. Data was analysed using STATA package version 12.
Socio-demographic characteristics (sex, age, HIV status of participant, and presence of a
BCG scar among the contacts) of the three remaining groups (uninfected contacts, latently
infected contacts, active TB cases) were compared. The Mann-Whitney U test was used for
comparing continuous characteristics, the chi-squared test for comparing categorical charac-
teristics. Graphs were generated to show the net baseline IP-10 distributions among the three
groups and levels of IP-10 were compared with pairwise comparisons made using the Mann-
Whitney U test. Receiver operating characteristic (ROC) analysis was carried out to determine
the sensitivity and specificity of using IP-10 to differentiate 1) individuals with LTBI from
uninfected individuals, 2) individuals with active TB from uninfected individuals, and 3) indi-
viduals with LTBI from individuals with active TB. Kappa statistics were used for assessing
agreement between IP-10 (using the optimal cut-point from the ROC analysis), TST and QFN
in differentiating individuals with LTBI from uninfected individuals. Spearman’s correlation
coefficient comparing levels of IFNγ generated by the QFN test and levels of MTB specific IP-
10 was calculated. Random effects logistic regression models were used to assess how proximity
of contact and biological risk factors were associated with the QFN, TST and IP-10 tests in the
diagnosis of LTBI.
Among active TB cases, we compared levels of IP-10 between HIV infected and uninfected
individuals using the Mann-Whitney U test and multivariable logistic regression. We also
assessed the association between TST diameter and levels of IFNγ from the QFN test, and
MTB specific IP-10. Lastly, we compared the baseline levels of MTB specific IP-10 among con-
tacts with negative TST/QFN tests at baseline that converted to positive TST/QFN tests at the
end of six months and also among contacts with positive TST/QFN tests that reverted to nega-
tive TST/QFN tests.
Results
Characteristics of study subjects
We enrolled 102 active TB cases and 291 contacts in the main cohort. The median (interquar-
tile range; IQR) number of contacts per active TB case was three (two-four). From this cohort,
IP-10 as a Biomarker in the Diagnosis of Latent Tuberculosis Infection
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we analysed whole blood culture supernatants from the QuantiFERON1-TB Gold In-Tube
assay from 237 contacts and 102 active TB cases at baseline. The contacts were grouped accord-
ing to their infection status. At baseline, there were 76 uninfected (QFN-TST-) individuals, 62
latently infected (QFN+TST+) individuals, and 99 contacts with discordant results (QFN+TST-
(92) or QFN-TST+ (7)). The contacts presented with different characteristics from their TB
index cases. The contacts were mostly female, of younger ages and HIV negative, while the
active TB cases were mostly male, older (because of the inclusion criteria) and were more likely
to be HIV positive (Table 1). The uninfected contacts were slightly younger and were more
likely to have a BCG scar compared to the contacts with LTBI.
In response to MTB specific antigens, contacts with LTBI had the highest production of IP-
10 (median (interquartile range (IQR)): 12,485pg/ml (10,565–17,445) at baseline, compared to
the uninfected contacts 1,530pg/ml (426–3,431) p<0.0001; and to the active cases 11,725pg/ml
(7,448–15,183), p = 0.01 (Fig 1A). By contrast, the active TB cases had very low responses to
the mitogen (phytohaemagglutinin (PHA)) stimulation (Fig 1B) while contacts with LTBI had
similar levels to uninfected contacts. We noted that index cases had high MTB-specific but low
mitogen-specific IP-10 responses (whereas contacts with LTBI had high responses to both)
we investigated the use of MTB-specific to mitogen PHA specific IP-10 ratios in diagnosing
latent and active TB, as well as in discriminating between LTBI and active TB among the three
groups. The MTB specific to mitogen specific ratio was slightly higher among the active TB
cases (median (IQR)): 5.8 (4.0–7.5) compared to contacts with LTBI 5.3 (-0.2–10.9), p = 0.01
(Fig 1C). A sub analysis was carried out based on HIV status which showed that MTB specific
to mitogen specific IP-10 ratio was significantly higher in the HIV negative active TB cases,
3.85 (1.57–6.82) compared to the HIV negative latently infected contacts, 1.62 (1.36–2.62),
p = 0.0004 (Fig 1D).
Potential of IP-10 as a diagnostic marker
We assessed the potential of IP-10 as a biomarker for the diagnosis of latent and active TB. At
a cut off of 8,239 pg/ml, IP-10 was able to differentiate between the uninfected and latently
infected contacts with a sensitivity of 87.1% (95% CI, 76.2–94.3) and specificity of 90.9% (95%
CI, 81.3–96.6) (Fig 2A). The mitogen specific responses were not able to diagnose LTBI (Fig
2B). The MTB-specific cut off for diagnosing active TB was lower at 4,858 pg/ml with a sensi-
tivity of 83.3% (95% CI, 74.7–89.9) and specificity of 84.9% (95% CI, 73.9–92.5) (Fig 2C), and
the mitogen specific responses still were not able to diagnose active TB disease (Fig 2D). When
the MTB specific to mitogen specific ratio was used, it was able to diagnose LTBI at a cut off
of 0.88 with a sensitivity of 96.4% (95% CI, 88.8–99.6) and specificity of 89.3% (95% CI, 79.3–
95.6). The ratio was also able to diagnose active TB at a cut off of 0.47 with a sensitivity of
96.7% (95% CI, 91.6–99.3) and specificity of 78.7% (95% CI, 66.9–87.8).
Discriminating LTBI and active TB
The active TB cases included in this study were adults above 18 years. For this analysis we
investigated whether MTB specific IP-10responses, mitogen specific IP-10 responses, and
MTB specific to mitogen specific ratios were able to differentiate between latently infected
household contacts that were above 18 years and active TB cases. We found that neither MTB
specific IP-10 responses nor mitogen specific IP-10 responses were able to differentiate
between LTBI infection and active TB disease (Fig 3A and 3B). The MTB specific to mitogen
specific ratio was also not able to clearly differentiate between LTBI and active TB with an
area under the ROC curve (AUC) (bootstrap confidence intervals (BS-CI) of 0.60 (0.50–0.71)
IP-10 as a Biomarker in the Diagnosis of Latent Tuberculosis Infection
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(Fig 3C). However, the MTB specific to mitogen specific ratio was able to differentiate LTBI
and active TB in HIV negative adults with an AUC of 0.70 (0.58–0.81) (Fig 3D).
Prevalence of LTBI
If IP-10 production were used to identify individuals with probable LTBI, based on the cut-
off of 8,239 pg/ml, this would give a baseline prevalence of latent tuberculosis among contacts
of 55%, compared to 32% with TST, and 65% with QFN. There was a strong agreement
between IP-10 and QFN in diagnosis of LTBI (83%, kappa = 0.65), moderate agreement
between IP-10 and TST (62%, kappa = 0.27), and poor agreement between QFN and TST
(50%, kappa = 0.16).
Comparing the performance of IP-10 with interferon gamma (IFNγ) in the
QFN test
Generally, there was a good correlation between IP-10 levels and IFNγ in the QFN test at base-
line among the contacts (Spearman correlation, p-value) of 0.77, p<0.0001, and among the
active TB cases (Spearman correlation of 0.63, p<0.0001) (S1 Fig) and this pattern was similar
among the three groups: uninfected contacts, latently infected contacts, and the active TB cases
(interaction p-value = 0.43).
Factors affecting response in the diagnostic tests
The study population included all age groups. The active TB cases were all adults above 18
years of age while the contacts were of all age groups, ranging from 1 year to 70 years. We car-
ried out a sub analysis among the contacts to investigate whether age influenced IP-10 produc-
tion. The different age groups for this analysis included 0–5 years, 6–12 years, 13–18 years and
above 18 years. The youngest contacts (0–5 year) had the lowest MTB-specific IP-10 produc-
tion among the uninfected contacts and the highest production among the latently infected
contacts (p<0.0001) (Fig 4A). Still among contacts with LTBI, the 0–5 age group had the high-
est mitogen-specific IP-10 responses (Fig 4B).
Table 1. Participants characteristics.
Variable Factor Uninfected n = 66* n (%) Latent TB n = 62 n (%) Active index case n = 102 n (%) p-value
Sex Female 41 (62) 40 (65) 44 (43) 0.009
Male 25 (38) 22 (35) 58 (57)
Age (years) 0–5 20 (30) 13 (21) 0 0.0001
6–10 15 (23) 4 (6) 0
11–15 14 (21) 6 (10) 0
16–20 4 (6) 4 (6) 16 (16)
21–25 3 (5) 13 (21) 22 (21)
26–30 10 (15) 22 (36) 64 (63)
HIV Negative 63 (95) 57 (92) 62 (61) 0.0001
Positive 3 (5) 5 (8) 40 (39)
Presence of BCG No 11 (17) 21 (34) 0.02
Yes 55 (83) 41 (66)
IP-10 pg/ml median (IQR) 1,530 (426–3,431) 12,485 (10,565–17,445) 11,725 (7,448–15,183) 0.0001
* 10 missing in uninfected group.
doi:10.1371/journal.pone.0146098.t001
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We assessed putative risk factors among the contacts for association with the different test
results (TST, QFN and IP-10) at baseline (Table 2). Gender and HIV status were not associated
with a positive result for any test. Increasing age was strongly associated with a positive QFN
and IP-10 test but not with TST positivity. QFN and IP-10 were both strongly positively associ-
ated with close proximity with the active TB case. The contacts who lacked a BCG scar were
most likely to have a positive test result for the TST and IP-10 tests, but there was a weaker
association for QFN.
Fig 1. Comparison of MTB specific IP-10 responses, mitogen specific IP-10 responses and MTB specific to mitogen specific ratio among
household contacts and active TB cases. Box graphs comparing medians A) MTB antigen specific IP-10 levels, B) mitogen specific IP-10 levels, and C)
MTB specific to mitogen specific ratio in uninfected contacts, LTBI contacts and active TB cases. IP-10 was measured in QFN supernatants from uninfected
contacts (negative to both TST and by QFN), LTBI contacts (positive in both TST and QFN), and active TB cases at baseline. Baseline uninfected contacts,
n = 66; latently infected contacts, n = 62; active TB cases n = 102. Pairwise comparisons were made using the Mann-Whitney U test
doi:10.1371/journal.pone.0146098.g001
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Thirty-nine percent of active TB cases (40/102) were HIV positive, while 5% (12/237) of the
contacts were HIV positive. We assessed for the influence of HIV on MTB specific IP-10
responses in the active TB cases and found that there was no significant difference in MTB spe-
cific IP-10 levels between the TB cases with HIV infection (mean (95%CI)) 10,631.2 pg/ml
(3,934.6–17,327.7) or without HIV infection 13,607.1 pg/ml (12,104–15,110.1) (Mann-Whit-
ney U test, p = 0.15). However, the mitogen specific IP-10 responses were lower among the
active TB cases that were HIV positive 5,349.2 pg/ml (-1,867.2–12,565.6) compared to those
that were HIV negative 7,735.4 pg/ml (6,462.6–9,008.2) (Mann-Whitney U test, p = 0.05). A
multivariate logistic regression analysis was then carried out among the active TB cases adjust-
ing for age and gender and found no association between HIV and MTB specific IP-10 levels
Fig 2. Investigating the diagnostic potential of IP-10 as a biomarker in the diagnosis of latent and active TB.Receiver operating characteristic curves
for MTB specific IP-10, mitogen specific, and MTB specific to mitogen stimulated ratio were analysed using the uninfected contacts (negative to both TST and
QFN) as the controls and the active TB cases as the diseased group. For the diagnosis of latent tuberculosis (A, and B); for diagnosis of active tuberculosis
(C and D).
doi:10.1371/journal.pone.0146098.g002
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(Adjusted odds ratio (95% CI), p-value) 0.93 (0.10–8.60), p = 0.95. This was repeated for MTB
specific mitogen levels and still found no association with HIV (AOR (95% CI), p-value) 0.91
(0.31–2.64), p = 0.87).
We further carried out another sub analysis to assess how HIV infection could have affected
IP-10 production among the household contact in the different age groups. Eleven of the con-
tacts with HIV were above 18 years, and there was no difference in either the MTB-specific IP-
10 or mitogen specific responses between the HIV negative and HIV positive in this group
(p = 0.24 and p = 0.74 respectively) (Fig 4C and 4D).
Fig 3. Potential of IP-10 to discriminate LTBI and active TB.Receiver operating characteristic curves to differentiate between latent and active
tuberculosis were analysed for the diagnosis of latent tuberculosis using MTB specific IP-10 responses (A), mitogen specific IP-10 responses (B). Adults
above 18 years were analysed for MTB specific to mitogen specific IP-10 ratio (C), and a sub analysis among HIV negative individuals (D).
doi:10.1371/journal.pone.0146098.g003
IP-10 as a Biomarker in the Diagnosis of Latent Tuberculosis Infection
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Relationship between IP-10 and IFNγ responses and TST diameters at
baseline and follow up
We assessed whether IP-10 and IFNγ levels from the QFN test were associated with TST diam-
eter (categorised as<5mm, 5-9mm, 10-14mm,>15mm) at baseline and six months later. The
contacts with a TST diameter of<5mm produced the lowest concentrations of IP-10 (Fig 5A)
and IFNγ (Fig 5B) at baseline compared with contacts with larger TST diameters. The pattern
was similar at the end of six months of follow up (Fig 5C and 5D).
Fig 4. The influence of age on MTB specific IP-10 responses andmitogen specific IP-10 responses among household contacts. Box graphs
comparing medians A) MTB antigen specific IP-10 levels, and B) mitogen specific IP-10 levels among the different age groups; C) MTB antigen specific IP-10
levels, and D) mitogen specific IP-10 levels among the different age groups categorized by their HIV infection status. The different age groups included 0–5,
n = 55; 6–12, n = 46; 13–17, n = 32; >18, n = 103, and the HIV negative, n = 225; and HIV positive, n = 12. Pairwise comparisons were made using the Mann-
WhitneyU test
doi:10.1371/journal.pone.0146098.g004
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Table 2. TB Exposure and Biological Risk Factors Associated with QFN or TST or IP-10 test results among household contacts exposed to active
TB cases.
Variable Factor¥ TST n1 = 263 QFN n2 = 277 IP-10 n3 = 237
Unadjusted Adjusted* Unadjusted Adjusted* Unadjusted Adjusted*
OR (95% CI); p-value
Sex Female (n1 = 154,
n2 = 159, n3 = 139)
1 1 1 1 1 1
Male (n1 = 109,
n2 = 118, n3 = 98)
0.75 (0.36–1.56)
p = 0.44
1.10 (0.55–2.19)
p = 0.77
0.97 (0.52–1.81)
p = 0.94
1.53 (0.79–2.96)
p = 0.20
0.65 (0.35–1.22)
p = 0.18
0.90 (0.46–1.76)
p = 0.77
Age (years) 0–5 (n1 = 68,
n2 = 68, n3 = 57)
1 1 1 1 1 1
6–12 (n1 = 49,
n2 = 50, n3 = 43)
0.74 (0.20–2.64) 0.79 (0.26–2.40) 0.93 (0.35–2.47) 1.18 (0.46–2.98) 1.66 (0.60–4.55) 2.08 (0.75–5.73)
13–18 (n1 = 32,
n2 = 37, n3 = 35)
0.44 (0.10–1.87) 0.70 (0.21–2.47) 3.21 (1.03–9.97) 4.59
(1.63–12.97)
3.50
(1.15–10.63)
4.65
(1.51–14.32)
>18 (n1 = 114,
n2 = 122, n3 = 102)
3.01 (1.06–8.56)
p = 0.01
1.95 (0.79–4.79)
p = 0.13
6.22
(2.22–17.42)
p = 0.0004
6.15
(2.48–15.25)
p = 0.0001
4.22
(1.62–10.99)
p = 0.01
3.99
(1.51–10.52)
p = 0.02
Relationship to
index case
Not ﬁrst degree
(n1 = 85, n2 = 99,
n3 = 85)
1 1 1 1 1 1
First degree
(n1 = 178, n2 = 178,
n3 = 152)
3.65 (1.58–8.44)
p = 0.002
2.29 (0.99–5.30)
p = 0.05
2.13 (1.13–4.03)
p = 0.01
1.27 (0.64–2.51)
p = 0.49
1.37 (0.73–2.58)
p = 0.31
0.82 (0.39–1.71)
p = 0.60
Proximity to index
case
Shared meals
(n1 = 50, n2 = 51,
n3 = 44)
1 1 1 1 1 1
Δ 1 missing n1, 3
missing n2, 2
missing n3
Cared for index case
(n1 = 65, n2 = 69,
n3 = 59)
5.20 (1.42–19.0) 3.40
(1.03–11.22)
5.69
(1.93–16.79)
3.40 (1.31–8.84) 5.20
(1.81–14.90)
3.57
(1.19–10.68)
Slept in same room
(n1 = 96, n2 = 104,
n3 = 90)
2.96
(0.85–10.32)
2.18 (0.70–6.82) 3.14 (1.22–8.10) 2.38 (1.02–5.54) 4.83
(1.74–13.36)
4.23
(1.39–12.88)
Slept in same room
and bed (n1 = 51,
n2 = 50, n3 = 42)
5.08
(1.22–21.03)
p = 0.06
3.05
(0.89–10.40)
p = 0.19
13.75
(3.63–52.08)
p = 0.0007
12.93
(3.78–44.16)
p = 0.0004
7.71
(2.29–25.95)
p = 0.004
9.42
(2.53–35.10)
p = 0.009
Daily duration of
contact with index
case
<6 hours (n1 = 44,
n2 = 44, n3 = 39)
1 1 1 1 1 1
>6 hours (n1 = 219,
n2 = 233, n3 = 198)
3.20 (1.03–9.86)
p = 0.04
3.02 (1.02–8.94)
p = 0.05
1.18 (0.50–2.78)
p = 0.68
1.30 (0.54–3.14)
p = 0.54
0.96 (0.40–2.27)
p = 0.93
0.89(0.34–2.33)
p = 0.82
Presence of a BCG
scar
Yes (n1 = 207,
n2 = 215, n3 = 188)
1 1 1 1 1 1
Δ 2 missing n2, 1
missing n3
No (n1 = 56, n2 = 60,
n3 = 48)
2.92 (1.29–6.60)
p = 0.01
2.38 (1.11–5.09)
p = 0.02
1.31 (0.57–2.98)
p = 0.51
1.24 (0.55–2.77)
p = 0.59
2.27 (1.06–4.85)
p = 0.03
2.23 (0.94–5.27)
p = 0.06
HIV status of
household contact
Negative (n1 = 247,
n2 = 261, n3 = 225)
1 1 1 1 1 1
Positive (n1 = 16,
n2 = 16, n3 = 12)
3.34
(0.73–15.15)
p = 0.11
0.89 (0.24–3.27)
p = 0.86
1.22 (0.28–5.16)
p = 0.78
0.27 (0.06–1.17)
p = 0.08
0.82 (0.21–3.24)
p = 0.78
0.36 (0.08–1.59)
p = 0.18
¥ n1 represents TST, n2 represents QFN, and n3 represents IP-10.
* All the above variables were adjusted for each other in the regression models.
doi:10.1371/journal.pone.0146098.t002
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High baseline IP-10 responses are associated with conversion of the
TST test from negative to positive
In this study, 52% (36/69) of the contacts had TST reversions and 10% (16/168) TST conver-
sions between baseline at six-months follow-up, while there were 7% (10/154) QFN reversions
and 17% (14/83) QFN conversions. The baseline concentrations of IP-10 were significantly
higher among the baseline TST negative contacts who proceeded to TST conversion, compared
to those who did not (Fig 6A), but there was no difference in baseline IP-10 among the contacts
with or without TST reversion (Fig 6B). Contrarily, there was no difference in baseline IP-10
among QFN-negatives who proceeded to QFN conversion, compared to those who did not
Fig 5. The relationship between TST diameter and IP-10 or IFNγ production in QuantiFERON test supernatants. Bar graphs show baseline and end of
follow up median comparisons of IP-10 levels (A and C) and IFNγ levels from the QFN test (B and D) with TST diameters. Comparisons were tested using the
Mann-Whitney U test.
doi:10.1371/journal.pone.0146098.g005
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(Fig 6C), whereas among QFN positive contacts, those who reverted had lower baseline con-
centrations of IP-10 than those who did not (Fig 6D).
Discussion
In this prospective study, we analysed whole blood QFN culture supernatants at baseline and
after six months for IP-10 responses and found that IP-10 is potentially a good diagnostic
marker for LTBI and active TB disease [31]. The biomarker was easy to detect, being produced
at very high levels even in children and in individuals with HIV infection [34, 47, 48]. A study
by Petrone et al., in the same setting in Uganda were not able to accurately diagnose active TB
in children using plasma IP-10. In addition, Holm et al., carried out a study in a similar setting
Fig 6. Assessing IP-10 concentrations among household contacts that converted their TST/QFN test results from negative to positive or reverted
their TST/QFN test results from positive to negative. Box graphs comparing median baseline MTB specific IP-10 levels among A) TST converters, B) TST
reverters, C) QFN converters, D) QFN reverters. IP-10 was measured in QFT supernatants in contacts at baseline. Contacts with TST conversions, n = 16; or
QFN conversions, n = 14 were compared with contacts who were persistently TST negative, n = 98 or persistently QFN negative, n = 46. Contacts with TST
reversions, n = 36 or QFN reversions, n = 10 were compared with contacts who were persistently TST positive, n = 5 or persistently QFN positive, n = 104.
Mann-Whitney U test A) p = 0.001, B) p = 0.21, C) p = 0.34, D) p <0.0001. Pairwise comparisons were made using the Mann-Whitney U test.
doi:10.1371/journal.pone.0146098.g006
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of a high TB burden and found that IP-10 performed well in diagnosing TB disease in adults
but not in children [43]. Both these studies showed low sensitivities of IP-10 in children. How-
ever, the children in the studies either had confirmed or probable TB disease, unlike the chil-
dren in our study who were healthy contacts. There was also heavy influence of HIV infection
in their findings, which was not demonstrated in our study. Furthermore, the children in our
study showed no signs or symptoms of severe malnutrition. The active TB cases in this study
had very low IP-10 responses following stimulation with the mitogen PHA compared to that of
contacts [49]. This could be as a result of immunosuppression by MTB or from HIV co-infec-
tion which may have led to low lymphocyte counts. However, we found that there was no asso-
ciation between the HIV status of either the TB cases or contacts and their MTB specific IP-10
levels.
The air borne nature of MTB transmission means that closer proximity to the index case
and longer duration interacting with the index case increases the risk of TB infectiousness [3,
50]. Therefore a good test to diagnose LTBI or active TB should correlate well with the extent
of TB exposure and would not be influenced by the BCG immunisation status of the individual
resulting in false positive results as seen with the TST [2, 5, 26, 51]. In this study, MTB specific
IP-10 was strongly associated with TB exposure making it comparable to TST and QFN in
diagnosing LTBI, and was not influenced by the presence of a BCG scar [34, 52].
Effects of BCG immunisation on TST positivity have been previously reported [18, 20, 25]
and could have contributed to the discordance between TST and QFN especially when BCG is
given at birth. The effects of BCG at birth can last for at least as long as 15 years [27]. In BCG
unvaccinated populations, there is better concordance between TST and the IGRA tests [23].
The effect of BCG on TST depends on the timing of the vaccine, the frequency at which it is
given, the type of BCG strain used in the vaccine, and the time since vaccination [27]. We
found higher MTB-specific IP-10 concentrations and TST positivity in those with lack of a
BCG scar, suggesting that BCG was conferring some protection in our setting [53, 54].
We assessed the performance of IP-10 to determine whether there was an added benefit of
using IP-10 as a potential biomarker in the IGRA test and found that IP-10 was comparable to
IFNγ [34]. IP-10 has the advantage of being easy to detect even in children or in persons with
HIV infection unlike the IGRA where there is evidence of many indeterminate results in the
same populations [41]. In this study, there was good agreement between IP-10 and QFN, mod-
erate agreement between IP-10 and TST and poor agreement between QFN and TST. This con-
trasts with a study by Pai, et al., in health care workers in India which is a high TB endemic
setting, which reported high TST and QFN agreement [28].
Similar to IFNγ in the IGRA, IP-10 was not able to differentiate between latent infection
and active TB disease [55–57]. Recent evidence by Wergeland, et al., demonstrated how IP-10
differentiated between active TB cases and LTBI or QFN negative controls [58]. The differences
in our findings could be explained by the differences in study design and populations. Their
study was carried out in a low TB endemic area, where they included only adult patients, they
defined LTBI based on only a positive QFN, and used multiplex cytokine assay to detect IP-10
which had much lower cut offs for detection. While our study was carried out in a high TB
endemic area, the study population included children and adults, we defined LTBI as positive
QFN and TST, and used an ELISA assay to detect IP-10 at higher cut offs. We further explored
whether MTB specific to mitogen specific IP-10 ratios could discriminate individuals with
LTBI from those with active TB. Despite the active TB cases having a slightly higher ratio,
when we performed the ROC analyses in the study subjects above 18 years, the AUC was 0.60
which showed that the MTB specific to mitogen specific ratios could not be used to differenti-
ate between LTBI and active TB. However, when we performed this analysis in the HIV nega-
tive population, we obtained an AUC of 0.7 which was able to discriminate between LTBI and
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active TB in this sub population. This finding is similar to work carried out by Jeong, et al.,
who found that MTB specific to mitogen induced IP-10 ratios could be used to differentiate
between latent infection and active TB disease irrespective of HIV status [49]. In the Jeong
study, MTB specific to mitogen specific IP-10 ratios could discriminate between LTBI and
active TB in individuals irrespective of their HIV status, while in our study, they could only dis-
criminate between the two disease states among HIV negative individuals. It was also of inter-
est to note that despite the location of the study area being in a low TB burden setting, the
active TB cases produced very high quantities of IP-10, almost four time as high as what the
active TB cases in our study (a high TB endemic setting) produced. This could have contrib-
uted to the high MTB specific to mitogen induced IP-10 ratios, and the ability to achieve an
AUC well above 0.8, thus allowing the ratio to adequately discriminate between LTBI and
active TB. They however used a multiplex cytokine assay to detect for IP-10 responses.
TST or DTH responses do not always correlate with IFNγ responses [59]. A low TST
response with high IGRA responses may also be attributed to constant exposure to non-tuber-
culosis mycobacteria which may cause anergy [26, 60] or boosting of DTH immune responses
from recent mycobacterial exposure which is easily detected by the IGRA and not TST [60].
Our household cohort had many children who presented with TST negative results. The find-
ings were similar to those reported by Mudido, et al., among Ugandan children despite BCG
immunisation at birth [29]. This could be an effect of HIV infection [61] but most of the con-
tacts in our study were HIV negative. It could also be as a result of malnutrition [4] though
none of the contacts presented with symptoms or signs of severe malnutrition. There have
been suggestions that differences in human leucocyte antigen (HLA) among individuals can
also lead to differences in DTH or IFNγ immune responses [62]. Another possible reason for
the differences in findings between studies could be related to the different manufacturers of
tuberculin used, with RT23 2TU or 1TU giving more positive TST results than 5TU PPD from
other sources [27]. We used RT23 2TU in our study but still detected few positive responses
using TST. A study by Floyd, et al., showed how TST results varied with latitude [63] and there
was a reduction in TST responses in the tropics. There could also be misclassification of BCG
status secondary to the use of the presence of a BCG scar as a surrogate [28], although over
80% of the contacts had a BCG scar. A study by Soysal, et al., found that presence of a BCG
scar was associated with reduced infection defined using IGRA but not TST to test for MTB
infection [64]. In our study, contacts with a BCG scar had lower responses on all the three
tests. Another possibility might be prenatal exposure to TB antigens in this highly endemic
area, resulting in tolerance.
When we compared IP-10 response with the different TST diameters, we found that the IP-
10 response increased with increasing TST diameters. We further investigated the relationship
of MTB specific IP-10 response with QFN and TST test reversions and conversions. Our study
had a high number of TST reversions which is not uncommon [65]. The baseline MTB specific
IP-10 response was marked among the contacts who converted their TST from negative to pos-
itive. This supports the ability of IP-10 to diagnose ‘recent TB infection’ in individuals classified
as having LTBI using the TST, and could suggest that high MTB specific IP-10 responses in
absence of the TST may point towards early infection. Further still, we think that such high IP-
10 responses might be a good discriminator of established MTB infections, as opposed to tran-
sient MTB-specific sensitisation. This could help identify people most likely to benefit from
chemoprophylaxis with isoniazid preventive therapy. A study by Buchwald, et al., also sug-
gested IP-10 as a potential marker of recent infection [66].
Interestingly, we also found that the contacts who reverted their QFN test produced lower
MTB specific IP-10 responses than those that had a persistent positive QFN test. Thus a low
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MTB specific IP-10 response in the presence of a negative QFN test may suggest a threshold of
exposure less likely to establish infection in such individuals.
The main limitation of this study was the absence of a gold standard for diagnosing LTBI
and this is a challenge for the development of any diagnostic test for LTBI. We used the combi-
nation of TST and QFN positivity to define LTBI and assess the performance of IP-10. The
other possible limitation could have been the choice of using QFN supernatants to assess for
IP-10 responses, although QFN samples have been used before to measure IP-10 responses
with similar results [40]. The inability to measure the effect of NTM on the three test responses
is another possible limitation. Lastly, IP-10 expression has been shown to be increased in a
number of infections including TB disease [34], which could affect its specificity as a biomarker
[67], but we however, found IP-10 responses to MTB-specific antigens to be highly specific for
TB infection and disease. A review by Ruhwald, et al., showed variability of findings on the
potential use of IP-10 as a biomarker in diagnosis of TB disease, as being influenced by differ-
ences in dilution of samples, type of samples used, assays to measure IP-10, and diagnostic cut-
offs used [34]. Our study however was able to demonstrate that IP-10 has a high potential of
being used to diagnose latent tuberculosis and in addition, it could be used as a marker of
recent infection with MTB and of individuals particularly likely to benefit from isoniazid pre-
ventive therapy.
Conclusion
High IP-10 concentrations were measured in QFN supernatants from latently infected con-
tacts compared to uninfected contacts or active TB cases. Therefore, IP-10 can be used to diag-
nose LTBI because it is easily detectable though active TB disease needs to be ruled out. The
baseline prevalence of LTBI using TST and QFN were 32% and 65% respectively. An IP-10
cut-off of 8,239 pg/ml maximised sensitivity/specificity compared to the QFN+TST+ standard.
Using this cut-off, the baseline LTBI prevalence was 55%. IP-10 performed well in differentiat-
ing contacts with either latent or active TB from those who were uninfected but was not able
to differentiate latent infection from active disease except when MTB specific to mitogen spe-
cific ratios were used in HIV negative adults. However, we also demonstrated the ability of IP-
10 to diagnose ‘recent TB infection’ and hence transmission in individuals classified as having
LTBI using the TST. Such strong IP-10 producers would be a likely target group to benefit
from chemoprophylaxis.
Supporting Information
S1 Fig. Correlation between IP-10 and interferon gamma (IFNγ) in the QFN test. Scatter
graphs showing the correlation between IP-10 levels and IFNγ among A) household contacts,
B) index cases.
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